Related Experiment Video
Updated: Jun 16, 2025
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal arterial resistance index before and after vericiguat administration: Should it be considered the fantastic
Francesco Natale1, Chiara Fusco2, Rossella Stigliani2
1Vanvitelli Cardiology Unit, Monaldi Hospital, Naples, Italy.
Insights
Vericiguat significantly reduces renal arterial resistance index (RRI) in heart failure (HF) patients. This finding suggests vericiguat may offer additional cardiovascular benefits beyond its primary therapeutic effects in HF management.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Heart failure (HF) is a chronic, progressive condition with limited options for full cardiac function recovery.
- Current HF management focuses on slowing disease progression, managing symptoms, and reducing hospitalizations.
- Vericiguat is an emerging add-on therapy for HF, showing promise without adverse renal effects.
Purpose of the Study:
- To investigate the effect of vericiguat on renal arterial resistance index (RRI) in patients with heart failure.
- To explore vericiguat's potential impact on cardiovascular damage markers in HF.
- To assess the safety and efficacy of vericiguat in a specific HF patient cohort.
Main Methods:
- A study involving 27 heart failure patients.
- Administration of vericiguat to the participants.
- Evaluation of renal arterial resistance index (RRI) before and after treatment.
Main Results:
- Vericiguat administration resulted in a significant reduction in RRI.
- The study observed a positive impact of vericiguat on a key indicator of cardiovascular damage.
Conclusions:
- Vericiguat demonstrates a significant reduction in RRI in HF patients.
- These findings suggest vericiguat may provide additional cardiovascular benefits in HF management.
- The drug's potential role in mitigating cardiovascular damage warrants further investigation.
Background:
Heart failure (HF) is a chronic-progressive disease. Once established, it is almost impossible to obtain a restitutio ad integrum of the cardiac function, but current strategies aim at slowing down the progression towards the terminal stages of the disease, which inevitably lead to the exitus. On the basis of these considerations, it appears clear that pharmacological interventions applied in this clinical condition should prevent first the development of the disease, by controlling the risk factors for HF thus reducing the onset of the disease, second slowing the disease evolution towards the terminal phases thus containing clinical symptoms and reducing the number of hospitalizations. In this scenario, the add-on therapy with vericiguat seems promising as reported in the VICTORIA study without affecting renal function. Several evidence indicates that renal arterial resistance index (RRI) seems to better reflect cardiovascular damage also in HF patients, thus affecting patients prognosis METHODS: In the present study we have analyzed the effect of vericiguat administration in 27 HF patients specifically evaluating RRI.
Results:
Vericiguat signicantly reduces RRI.
Conclusions:
The findings of the present study seems to indicate that vericiguat, beyond its primary mechanism of action, might offer an additional advantage in HF patients.
Related Concept Videos
01:20Vascular Resistance
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System